Our team

Board of Directors

Luis Sánchez-Lafuente

Chairman

Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA

Carles Domènech

Executive chairman

Executive Chairman, CSO and co-Founder of Ability Pharmaceuticals, SL

 

José Manuel Valadés

General secretary

Lawyer, partner and founder of the law firm Alliant Abogados

Miquel Àngel Bonachera

Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.

Sergi Audivert

Chief executive officer and co-founder of AB Biotics, SA. 
BSc/MSc in food technology and MBA.

Sara Secall

Operating Partner & Life Sciences Investment Director of Inveready Asset Management

German Cutillas

Venture Capital Partner at Fitalent (grup Everis)

Roger Piqué

Managing director and co-founder of Inveready Seed Capital SCR.

LATEST NEWS

25.03.2020

News

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG